Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: A randomized multicenter controlled trial in subjects with osteoarthritis of the knee

Advances in Therapy

Volumn 27, Issue 10, 2010, Pages 731-742

  Levy, Robert M ^a   Khokhlov, Alexander ^b   Kopenkin, Sergey ^c   Bart, Boris ^c   Ermolova, Tatiana ^d   Kantemirova, Raiasa ^e   Mazurov, Vadim ^d   Bell, Marjorie ^f   Caldron, Paul ^g   Pillai, Lakshmi ^a   Burnett, Bruce P ^a  

^a PRIMUS PHARMACEUTICALS INC   (United States)

^b Yaraslavl State Medical Academy   (Russian Federation)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^e Federal State Institute St Petersburg Scientific   (Russian Federation)

^f ClinDataServices   (United States)

^g Arizona Arthritis and Rheumatology Research   (United States)

Author keywords

5 Lipoxygenase; Clinical trial; Cyclooxygenase; Flavocoxid, flavonoids; Naproxen; Osteoarthritis

Indexed keywords

FLAVOCOXID; FLAVONOID; LIPOXYGENASE INHIBITOR; NAPROXEN; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; CATECHIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; EAR NOSE THROAT DISEASE; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATECHIN; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS, KNEE; RESPIRATORY TRACT DISEASES;

EID: 79952116933     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0064-z     Document Type: Article

References (50)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
2. Andersen RE, Crespo CJ, Ling SM, Bathon JM, Bartlett SJ. Prevalence of significant knee pain among older Americans: results from the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc. 1999;47:1435-1438.
3. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol. 2006;33:2271-2279.
4. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol. 2008;35:677-684. (Pubitemid 351500066)
5. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646-656. (Pubitemid 37254686)
6. Sale JE, Gignac M, Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol. 2008;35:335-342. (Pubitemid 351281157)
7. Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res. 2005;17:255-263. (Pubitemid 46190142)
8. Jinks C, Jordan K, Croft P. Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 2007;46:877-881. (Pubitemid 47061725)
9. Ethgen O, Vanparijs P, Delhalle S, Rosant S, Bruyere O, Reginster JY. Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res. 2004;13:321-330. (Pubitemid 38392260)
10. Kirchner T, Aparicio B, Argentieri DC, Lau CY, Ritchie DM. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids. 1997;56:417-423. (Pubitemid 27276173)
11. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem. 2001;36:109-126. (Pubitemid 32304514)
12. Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg. 2006;19:191-197.
13. Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum. 2004;50:3925-3933.
14. Brune K. Safety of anti-inflammatory treatment - new ways of thinking. Rheumatology (Oxford). 2004;43(suppl. 1):i16-20.
15. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742-747. (Pubitemid 23185096)
16. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759-770. (Pubitemid 41099056)
17. Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985;78:992-1000. (Pubitemid 15021265)
18. Deray G. Renal and cardiovascular effects of nonsteroidal anti-inflammatories and selective cox 2 inhibitors. Presse Med. 2004;33:483-489. (Pubitemid 38489876)
19. Salahudeen AK, Reckelhoff JF, Morrow JD, Roberts LJ, 2nd. F2-isoprostanes and the kidney. Drug News Perspect. 1998;11:287-290.
20. Roberts L, Morrow J. The generation and actions of isoprostanes. Biochim Biophys Acta. 1997;1345:121-135.
21. Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis. 2001;60:627-631.
22. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
23. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
24. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA. 2003;100:10937-10941. (Pubitemid 37140131)
25. Eisen G. Lack of correspondence of risk factors and clinical GI outcomes for patients on nonsteroidal anti-inflammatory drugs (NSAIDs): analysis from the Celecoxib Long-term Arthritis Safety Study (CLASS). Gasteroenterology. 2001;120:A553.
26. Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008;10:43-48.
27. Cicero AF, Derosa G, Gaddi A. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging. 2005;22:393-403.
28. Bertolini A, Ottani A, Sandrini M. Dual acting antiinflammatory drugs: a reappraisal. Pharmacol Res. 2001;44:437-450. (Pubitemid 34014322)
29. Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Brit J Pharmacol. 2009;157:1410-1418.
30. Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food. 2007;10:442-451. (Pubitemid 47493490)
31. Burnett BP, Pillai L, Levy RM, editors. Flavocoxid, a natural novel flavonoid-based anti-inflammatory with a broad mechanism of action provides safe and effective inflammatory management of disease. Presented at: Society for Biomolecular Science; April 11-15, 2010; Phoenix, AZ.
32. Cao GH, Prior RL. Measurement of oxygen radical absorbance capacity in biological samples. Methods Enzymol. 1999;299:50-62.
33. Morgan SL, Baggott JE, Moreland L, Desomond R, Kendrach A. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods. 2008;12:1-6.
34. Levy R, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutrition Res. 2009;29:298-304.
35. Burnett BP, Silva S, Mesches MH, Jia Q. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem. 2007;31:797-825. (Pubitemid 350161718)
36. Baron G, Tubach F, Ravaud P, Logeart I, Dougados M. Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis Rheum. 2007;57:633-638. (Pubitemid 46764054)
37. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 1999;38:355-361. (Pubitemid 29507186)
38. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain. 2002;100:55-64. (Pubitemid 35305123)
39. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591-511.
40. Bertolini A, Ottani A, Sandrini M. Dual acting antiinflammatory drugs: a reappraisal. Pharmacol Res. 2001;44:437-450. (Pubitemid 34014322)
41. Pelletier JP, Martel-Pelletier J, Raynauld JP. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res Ther. 2006;8:206.
42. Naftalin RJ, Afzal I, Cunningham P, et al. Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. Br J Pharmacol. 2003;140:487-499. (Pubitemid 37330493)
43. Fiorani M, Accorsi A, Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Radic Res. 2003;37:1331-1338. (Pubitemid 37441716)
44. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742-747. (Pubitemid 23185096)
45. Badr KF. Five-lipoxygenase products in glomerular immune injury. J Am Soc Nephrol. 1992;3:907-915.
46. Pretorius JC. Flavonoids: a review of its commercial application potential as anti-infective agents. Curr Med Chem. 2003;2:335-353.
47. Yamada H, Takuma N, Daimon T, Hara Y. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study. J Altern Complement Med. 2006;12:669-672. (Pubitemid 46141019)
48. Manoukian AV, Carson JL. Nonsteroidal antiinflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf. 1996;15:64-71.
49. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40:201-208. (Pubitemid 27114083)
50. Alatalo PI, Koivisto HM, Hietala JP, Puukka KS, Bloigu R, Niemela OJ. Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. Am J Clin Nutr. 2008;88:1097-1103.